Keith A. Moore;Jason D. Modest;John W. Facemire;Ralph A. Heasley;Jeffrey S. Greiwe
发明人:
Ralph A. Heasley,Keith A. Moore,Jeffrey S. Greiwe,John W. Facemire,Jason D. Modest
申请号：
US11346710
公开号：
US08968777B2
申请日:
2006.02.03
申请国别(地区):
US
年份:
2015
代理人:
摘要：
Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.
